Transcutaneous Pulsed Radiofrequency for the Treatment of Diabetic Peripheral Neuropathy Pain
Can a Non-interventional Pulsed Radiofrequency Device Relieve Pain and Improve Function in Patients With Diabetic Neuropathy That Are Refractory to Medication? A Single Blind Randomized Placebo-controlled Trial
The purpose of this study is to determine if a non-invasive, electrical pulsed radio frequency (PRF) device can relieve pain and improve function in patients suffering from diabetic nerve pain in their feet, known as pedal diabetic peripheral neuropathy. Patients with this condition often experience severe pain, burning sensations, numbness, and tingling. Current medications for diabetic nerve pain often have unwanted side effects or do not provide sufficient relief.
In this single-blind, randomized trial, participants are assigned to receive either an active PRF treatment or a placebo (sham) treatment. Both treatments involve placing the device safely behind the knee (targeting the sciatic nerve) for 10 minutes, once a week for 3 weeks. The main question this study aims to answer is whether the active PRF treatment reduces nerve pain and symptoms significantly more than the placebo, measured by standard symptom questionnaires over a 6-month period.
연구 개요
상태
상세 설명
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, often presenting as a chronic, symmetrical, length-dependent sensorimotor polyneuropathy. Patients frequently experience neuropathic pain, hyperalgesia, allodynia, and paraesthesia in the lower extremities. Because pharmacological treatments for painful DPN are often ineffective and complicated by adverse side effects, there is a significant unmet clinical need for alternative, non-pharmacological therapies. This single-blind, randomized, placebo-controlled clinical trial evaluates the efficacy of a transcutaneous electrical pulsed radio frequency (PRF) device in alleviating the pain and sensory symptoms associated with pedal DPN.
Patients diagnosed with pedal DPN who scored 4 or higher on the DN4 neuropathic pain diagnostic test were randomized into two parallel groups: an active treatment group and a placebo group. To ensure successful patient blinding, participants were advised that they might not feel a physical sensation during the treatment, which aligns with the natural sensory loss (numbness/paraesthesia) commonly experienced by this patient population. Care providers and investigators administering the interventions were unblinded.
The treatment protocol involved mapping the sciatic nerve in the popliteal fossa posteriorly at the knee. The active or placebo device was then applied bilaterally at this site for 10 minutes. Interventions were administered once weekly for three consecutive weeks.
Clinical efficacy was assessed using validated patient-reported outcome measures. The primary outcome evaluated changes in neuropathic pain and symptoms using the DN4 test, while the secondary outcome measured pain severity and interference with daily life using the Brief Pain Inventory-Short Form (BPI-SF). Data was collected at baseline, immediately following the third treatment, and at subsequent follow-up visits at 1, 3, and 6 months to evaluate both immediate and sustained therapeutic effects.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Gauteng
-
Johannesburg, Gauteng, 남아프리카
- Centre for Diabetes and Endocrinology (CDE), Houghton
-
Johannesburg, Gauteng, 남아프리카
- Clinical Sites - West Johannesburg
-
Johannesburg, Gauteng, 남아프리카
- Diabetic Clinic at the Charlotte Maxeke Hospital
-
Krugersdorp, Gauteng, 남아프리카
- Clinical Sites - Krugersdorp
-
Pretoria, Gauteng, 남아프리카
- CDE / Clinical Sites - Pretoria
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Diagnosis of pedal Diabetic Peripheral Neuropathy.
- A score of 4 or greater than 4/10 on the DN4 Test.
- Naive to (no previous experience with) the electrical pulsed radio frequency current treatment.
Exclusion Criteria:
- Current pregnancy.
- Presence of a pacemaker.
- Presence of a peripheral or spinal cord stimulator.
- Presence of metal implants in the knee and/or hip.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group A: Active Transcutaneous Pulsed Radio Frequency
Patients in this group received the active electrical pulsed radiofrequency current treatment.
The device was applied bilaterally at the sciatic nerve in the popliteal fossa.
Each treatment session lasted for 10 minutes.
The intervention was administered once weekly for three consecutive weeks.
|
Active transcutaneous electrical pulsed radio frequency stimulation.
The device is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks.
다른 이름들:
|
|
가짜 비교기: Group B: Placebo / Sham Device
Patients in this group received a placebo (sham) treatment designed to mimic the active device.
The placebo device was applied bilaterally at the sciatic nerve in the popliteal fossa.
Each placebo session lasted for 10 minutes.
The sham intervention was administered once weekly for three consecutive weeks.
|
A sham device designed to look and operate like the active device but delivering no therapeutic current.
It is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks to mimic the active treatment.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Neuropathic Pain and Symptoms as Measured by the DN4 Test
기간: Baseline, prior to the third treatment (Week 3), and at 1, 3, and 6 months after the last treatment.
|
The DN4 (Douleur Neuropathique 4) questionnaire is a screening tool used to identify neuropathic pain and symptoms.
It consists of 7 subjective questions regarding sensory symptoms (e.g., burning, painful cold, electric shocks, tingling, pins and needles, numbness) and 3 objective tests (hypoesthesia to touch, pinprick, and tactile allodynia).
The maximum score is 10 points.
A score of 4 or greater out of 10 represents a positive diagnosis of neuropathic pain.
Higher scores indicate a greater severity of neuropathic pain and symptoms.
|
Baseline, prior to the third treatment (Week 3), and at 1, 3, and 6 months after the last treatment.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Pain Severity as Measured by the Brief Pain Inventory-Short Form (BPI-SF)
기간: Baseline, after the first treatment (Week 1), second treatment (Week 2), third treatment (post-treatment at Week 3), and at 1, 3, and 6 months after the last treatment.
|
The BPI-SF is a validated patient-reported questionnaire that evaluates pain.
This outcome focuses on the Pain Severity subscale, which assesses worst, least, average, and present pain using an 11-point numerical rating scale.
Scores range from 0 to 10, where 0 equals "no pain" and 10 equals "pain as bad as you can imagine".
Higher scores indicate greater pain severity.
|
Baseline, after the first treatment (Week 1), second treatment (Week 2), third treatment (post-treatment at Week 3), and at 1, 3, and 6 months after the last treatment.
|
|
Change in Pain Interference as Measured by the Brief Pain Inventory-Short Form (BPI-SF)
기간: Baseline, after the first treatment (Week 1), second treatment (Week 2), third treatment (post-treatment at Week 3), and at 1, 3, and 6 months after the last treatment.
|
The BPI-SF also evaluates how much pain interferes with various aspects of the patient's daily life.
This includes general activities, work, sleep, walking ability, mood, relations with other people, and overall quality of life.
Interference is measured using an 11-point numerical rating scale ranging from 0 to 10, where 0 equals "does not interfere" and 10 equals "completely interferes".
Higher scores indicate greater interference with daily functioning.
|
Baseline, after the first treatment (Week 1), second treatment (Week 2), third treatment (post-treatment at Week 3), and at 1, 3, and 6 months after the last treatment.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Phyllis P Berger, Faculty: University of the Witwatersrand
- 연구 책임자: Stanley S Landau, Centre for Diabetes and Endocrinology (CDE)
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M161037
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .